JTO Clinical and Research Reports (Oct 2022)

Assessing Oncologists’ Attitudes Concerning Comprehensive Genomic Profiling in Stage IV Lung Adenocarcinoma in Brazil

  • Aline F. Fares, MD, MSc,
  • Pedro H. Martinez,
  • Pedro H. Farina,
  • Isaac Bicalho de Souza,
  • Daniel V. Araújo, MD,
  • Narayana S. Paiva,
  • Ligia F. Orlando,
  • Tatiana Elias Colombo, PhD,
  • Eldsamira Mascarenhas, MD, MSc,
  • Ana Caroline Z. Gelatti, MD, MSc,
  • Clarissa Baldotto, MD, PhD,
  • Mauro Zukin, MD, PhD,
  • Luiz Henrique Araujo, MD, PhD,
  • Clarissa Mathias, MD, PhD,
  • Gustavo Werutsky, MD, PhD,
  • Gilberto de Castro, Jr., MD, PhD,
  • Vladmir C. Cordeiro de Lima, MD, PhD

Journal volume & issue
Vol. 3, no. 10
p. 100402

Abstract

Read online

Introduction: Advances in comprehensive genomic profiling (CGP) of lung adenocarcinomas (LUADs) led to personalized treatment for patients. This study evaluated medical oncologists’ attitudes toward CGP in a scenario where sponsored funding for CGP was available. Methods: We designed an online survey assessing CGP use and treating physicians’ confidence, composed of three self-confidence domains, which are as follows: confidence in interpreting CGP results, confidence in treating oncogenic-driven LUAD, and confidence in managing tyrosine kinase inhibitor adverse events. The survey was distributed to medical oncologists who treat lung cancer in Brazil. Comparisons between groups were performed using the chi-square or Fisher’s exact test. Univariable and multivariable (adjusted OR) analyses were performed. Results: Among 104 respondents who treat patients with lung cancer, 55% were from the Southeast region, 28% had high lung cancer clinical load, and 33% had in-house molecular testing. More than half (51%) of the participants request CGP systematically to stage IV LUAD. As for provider confidence, 67% stated being confident in all three domains: 76% confident in interpreting CGP, 84% confident in treating oncogenic-driven LUAD, and 81% in managing tyrosine kinase inhibitor adverse events. Providers’ confidence was associated with systematically requesting CGP to stage IV LUAD (p = 0.013). After controlling for the variables of interest, systematic requesting CGP for stage IV LUAD revealed a significant association with the provider’s confidence (adjusted OR = 0.35, p = 0.028, 95% CI: 0.14–0.84). The major challenge for properly requesting CGP was the long turnaround time and the fear of treatment delays. Conclusions: Even though CGP for stage IV LUAD in Brazil is fully sponsored, only half of the oncologists in our survey systematically request it.. Requesting CGP was associated with providers’ confidence. Improving access and promoting providers’ awareness of CGP utility is necessary to increase CGP use and better inform treatment decisions.

Keywords